The impact of human leukocyte antigen matching on transplant complications and immunosuppression dosage

Human Immunology

Volumn 68, Issue 6, 2007, Pages 491-499

  Aydingoz, Selda Emre ^a   Takemoto, Steven K ^a   Pinsky, Brett W ^a   Salvalaggio, Paolo R ^a   Lentine, Krista L ^a   Willoughby, Lisa ^a   Hoover, Beverly ^a   Burroughs, Thomas A ^a   Schnitzler, Mark A ^a   Graff, Ralph ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complication; HLA matching; Immunosuppression; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIARRHEA; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HLA MATCHING; HUMAN; HYPOTHESIS; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRANSPLANTATION;

GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSION; MULTIVARIATE ANALYSIS; REGISTRIES; TISSUE DONORS; TRANSPLANTS;

EID: 34248136067     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2007.02.004     Document Type: Article

References (40)

1. Takemoto S., Port F.K., Claas F.H., and Duquesnoy R.J. HLA matching for kidney transplantation. Hum Immunol 65 (2004) 1489
2. Gjertson D.W., Terasaki P.I., Takemoto S., and Mickey M.R. National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs. N Engl J Med 324 (1991) 1032
3. Takemoto S., Terasaki P.I., Cecka J.M., Cho Y.W., Gjertson D.W., and The UNOS Scientific Renal Transplant Registry. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. [see comments]. N Engl J Med 327 (1992) 834
4. Takemoto S.K., Terasaki P.I., Gjertson D.W., and Cecka J.M. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 343 (2000) 1078
5. Opelz G., Wujciak T., Dohler B., Scherer S., and Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1 (1999) 334
6. Connolly J.K., Dyer P.A., Martin S., Parrott N.R., Pearson R.C., and Johnson R.W. Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation 61 (1996) 709
7. Pirsch J.D., Ploeg R.J., Gange S., D'Alessandro A.M., Knechtle S.J., Sollinger H.W., Kalayoglu M., and Belzer F.O. Determinants of graft survival after renal transplantation. Transplantation 61 (1996) 1581
8. Hardinger K.L., Brennan D.C., Lowell J., and Schnitzler M.A. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 17 (2004) 609
9. Woodward R.S., Schnitzler M.A., Baty J., Lowell J.A., Lopez-Rocafort L., Haider S., Woodworth T.G., and Brennan D.C. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3 (2003) 590
10. Kasiske B.L., Snyder J.J., Gilbertson D., and Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 (2003) 178
11. Lentine K.L., Brennan D.C., and Schnitzler M.A. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 16 (2005) 496
12. Lentine K.L., Schnitzler M.A., Abbott K.C., Li L., Burroughs T.E., Irish W., and Brennan D.C. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 46 (2005) 720
13. Roberts J., Port F., Wolfe R., Rush S., Bragg J., Ashby V., DA D., Wynn J., and Held P. Eliminating points for HLA B matches benefits access to kidney transplantation for minorities with minimally increased risk of graft loss. (abstract). Am J Transplant 2 (2002) 146
14. Roberts J.P., Wolfe R.A., Bragg-Gresham J.L., Rush S.H., Wynn J.J., Distant D.A., Ashby V.B., Held P.J., and Port F.K. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 350 (2004) 545
15. Ojo A.O., Hanson J.A., Meier-Kriesche H., Okechukwu C.N., Wolfe R.A., Leichtman A.B., Agodoa L.Y., Kaplan B., and Port F.K. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 12 (2001) 589
16. Appendix 3A. Richmond, United Network for Organ Sharing, 2006, www.unos.org.
17. Hebert P.L., Geiss L.S., Tierney E.F., Engelgau M.M., Yawn B.P., and McBean A.M. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14 (1999) 270
18. Takemoto S.K., and Terasaki P.I. Evaluation of the transplant recipient and donor: molecular approach to tissue typing, flow cytometry and alternative approaches to distributing organs. Curr Opin Nephrol Hypertens 6 (1997) 299
19. Takemoto S., Terasaki P.I., Gjertson D.W., and Cecka J.M. Equitable allocation of HLA-compatible kidneys for local pools and minorities. N Engl J Med 331 (1994) 760
20. McKenna R.M., Lee K.R., Gough J.C., Jeffery J.R., Grimm P.C., Rush D.N., and Nickerson P. Matching for private or public HLA epitopes reduces acute rejection episodes and improves two-year renal allograft function. Transplantation 66 (1998) 38
21. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 3 (2003) 665
22. Cai J., and Terasaki P.I. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 66 (2005) 334
23. Halloran P.F., Melk A., and Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Socf Nephrol 10 (1999) 167
24. Jindal R.M., and Hariharan S. Chronic rejection in kidney transplants. An in-depth review. Nephron 83 (1999) 13
25. Port F.K., Bragg-Gresham J.L., Metzger R.A., Dykstra D.M., Gillespie B.W., Young E.W., Delmonico F.L., Wynn J.J., Merion R.M., Wolfe R.A., and Held P.J. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation 74 (2002) 1281
26. Held P.J., Kahan B.D., Hunsicker L.G., Liska D., Wolfe R.A., Port F.K., Gaylin D.S., Garcia J.R., Agodoa L.Y., and Krakauer H. The impact of HLA mismatches on the survival of first cadaveric kidney transplants [see comments]. N Engl J Med 331 (1994) 765
27. Terasaki P.I., Cecka J.M., Gjertson D.W., and Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors [see comments]. N Engl J Med 333 (1995) 333
28. 2005 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant Data 1995-2004. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI. Table 5. 2005;4c:5.
29. Salvadori M., Bertoni E., Rosati A., and Zanazzi M. Post-transplant diabetes mellitus. J Nephrol 16 (2003) 626
30. Webster A., Woodroffe R.C., Taylor R.S., Chapman J.R., and Craig J.C. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev (2005) (4):CD003961
31. Helderman J.H., and Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 13 (2002) 277
32. Miller L.W. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2 (2002) 807
33. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol 14 (2003) 1940
34. Flechner S.M., Friend P.J., Brockmann J., Ismail H.R., Zilvetti M., Goldfarb D., Modlin C., Mastroianni B., Savas K., Devaney A., Simmonds M., and Cook D.J. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 5 (2005) 3009
35. Woodward R.S., Schnitzler M.A., Lowell J.A., Spitznagel E.L., and Brennan D.C. Effect of extended coverage of immunosuppressive medications by medicare on the survival of cadaveric renal transplants. Am J Transplant 1 (2001) 69
36. Gallagher M.P., Hall B., Craig J., Berry G., Tiller D.J., and Eris J. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 78 (2004) 1653
37. Nattinger A.B., Laud P.W., Bajorunaite R., Sparapani R.A., and Freeman J.L. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39 (2004) 1733
38. Leung K.M., Hasan A.G., Rees K.S., Parker R.G., and Legorreta A.P. Patients with newly diagnosed carcinoma of the breast: validation of a claim-based identification algorithm. J Clin Epidemiol 52 (1999) 57
39. Stirnemann P.M., Takemoto S.K., Schnitzler M.A., Brennan D.C., Abbott K.C., Salvalaggio P., Burroughs T.E., Gavard J.A., Willoughby L.M., and Lentine K.L. Agreement of immunosuppression regimens described in medicare pharmacy claims with the organ procurement and transplantation network survey. J Am Soc Nephrol 17 (2006) 2299
40. Gaston R.S., Ayres I., Dooley L.G., and Diethelm A.G. Racial equity in renal transplantation. The disparate impact of HLA-based allocation. J Am Med Assoc 270 (1993) 1352